2024-03-29T14:38:00Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_681BF8D23E08
2024-03-23T02:28:44Z
serval:BIB_681BF8D23E08
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
10.1200/JCO.2008.21.3330
19620483
000269064300017
Le Cesne
A.
author
Van Glabbeke
M.
author
Verweij
J.
author
Casali
P.G.
author
Findlay
M.
author
Reichardt
P.
author
Issels
R.
author
Judson
I.
author
Schoffski
P.
author
Leyvraz
S.
author
Bui
B.
author
Hogendoorn
P.C.
author
Sciot
R.
author
Blay
J.Y.
author
article
2009
Journal of Clinical Oncology
1527-7755[electronic]
journal
27
24
3969-3974
Antineoplastic Agents/therapeutic use
Disease Progression
Gastrointestinal Stromal Tumors/drug therapy
Gastrointestinal Stromal Tumors/mortality
Humans
Piperazines/therapeutic use
Pyrimidines/therapeutic use
eng
60_published
Publication types: Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't Publication Status: ppublish